Loading...
NPI 1255361069 · Alexandria, LA · Rheumatology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Mohammad Shbeeb is a rheumatology physician provider located in Alexandria, Louisiana. This profile covers 25 Medicare and 1 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Mohammad Shbeeb |
| Address | 3349 Masonic Dr |
| City | Alexandria |
| State | LA |
| ZIP | 71301 |
| Taxonomy | Rheumatology Physician |
| NPI Enumerated | July 4, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $1.8M |
| Medicaid | $4.2K |
This provider’s billing is overwhelmingly Medicare-driven: Total Medicare revenue is $1.8M compared with Total Medicaid revenue of $4.2K, indicating an effectively single‑payer (Medicare) practice at scale. Medicaid receipts are negligible relative to Medicare, so Medicaid does not materially contribute to the provider’s overall revenue profile.
Revenue concentration on Medicare is high: the precomputed top three Medicare codes account for 67.7% of Medicare revenue. The largest single Medicare revenue driver is J0129 ($743.3K revenue, 41.5% of Medicare revenue), followed by J1602 ($283.9K, 15.8%) and J0717 ($185.6K, 10.4%), showing a narrow set of biologic drug codes dominate the payer-side revenue mix.
Medicaid revenue is entirely concentrated in a single E/M code: the precomputed top-three share is 100.0% and Medicaid revenue is entirely from 99213 (1.1K claims, $4 avg paid/claim, $4.2K revenue). This means all recorded Medicaid activity is routine established outpatient visits rather than drug- or infusion-driven services.
The code mix and descriptions indicate an infusion‑centric rheumatology practice. High-revenue biologic drug codes (J0129, J1602, J0717, J1745, J0897) and frequent use of infusion/administration items (96413, 96415, J7050) point to regular in-office administration of injectable biologics and the nursing/chair-time infrastructure required to deliver them.
Competitive standing is mixed by code: J0129 ranks #104 of 1221 nationally and sits in the upper peer tier (reported at the 91th percentile), and J1602 is at the 80th percentile, indicating stronger-than-average national participation in those biologics. Other biologic codes such as J0717 sit closer to median peer volumes (48th percentile), so the practice is a meaningful national participant for a subset of drugs rather than a consistent top-tier operator across all biologics.
Several utilization metrics are statistical outliers for administration and E/M services. Medicare 99213 is labeled an "extreme outlier" (rank #799 of 457151, 100th percentile) reflecting very high established-visit billing to Medicare, while infusion administration codes show unusually high activity (96413 at the 96th percentile labeled "notably above typical" and 96415 at the 95th percentile labeled "notably above typical"), supporting the conclusion of heavy infusion throughput.
Tenure and specialty alignment support the clinical pattern observed: the provider is enumerated as of 2006-07-04 (~20 years ago) and is listed under Rheumatology Physician taxonomy, which is consistent with the observed revenue mix dominated by biologic injections and frequent established outpatient visits. The longevity plus the infusion-heavy mix suggests an established rheumatology infusion service in the Alexandria, LA market.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
25 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 22,530 | $30 | $743.3K |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | 25,810 | $10 | $283.9K |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 46,400 | $1 | $185.6K |
| J0897 | Injection, denosumab, 1 mg | 9,540 | $20 | $171.7K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 5,230 | $30 | $136K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 2,050 | $60 | $129.2K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 680 | $90 | $63.1K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 190 | $90 | $16K |
| 96401 | The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient. | 250 | $50 | $13.5K |
| 99204 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider… | 120 | $110 | $12.8K |
Showing 1–10 of 25
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 25 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
25 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J1602 | 8 | 10 | 26,920 | $10 | $526.5K |
| J0129 | 4 | 10 | 9,490 | $30 | $506.1K |
| J0717 | 6 | 10 | 55,200 | $1 | $263K |
| J0897 | 11 | 70 | 3,120 | $20 | $105.6K |
| J1745 | 1 | 10 | 3,110 | $30 | $80K |
| 96413 | 4 | 70 | 140 | $90 | $22.8K |
| 99214 | 2,260 | 6,670 | 110 | $80 | $16.5K |
| 96401 | 12 | 50 | 130 | $50 | $12.9K |
| 99213 | 4 | 6,060 | 70 | $50 | $8.1K |
| 96365 | 73 | 80 | 60 | $40 | $6.4K |
Showing 1–10 of 25
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 1,050 | $1 | $4.2K |
How this provider's Medicaid billing volume and revenue compare to other Louisiana providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Louisiana median
1 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 1,652 | 3,230 | 1,120 | $30 | $204.3K |
Other providers in the same ZIP code as Mohammad Shbeeb, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.